Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DIGILITI MONEY GROUP, INC.CAFN · Entity 174754 | Director | August 17, 2016 | October 24, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DIGILITI MONEY GROUP, INC.
Report date August 17, 2016 · Filed October 24, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.85 · Expires 2021-08-17 | Direct | 8,000 |
Reported balance
After 2016-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-08-17 · Grant · Acquired 8,000 · Balance 8,000 F1: This stock option vests in three equal installments on August 17, 2016, 2017 and 2018 |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option vests in three equal installments on August 17, 2016, 2017 and 2018
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SkinHealth Systems Inc.
Report date August 10, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.85 · Expires 2031-05-06 | Direct | 0 |
Reported balance
After 2023-08-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-10 · Disposition to issuer · Disposed 372,000 · Balance 0 F1: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.85 · Expires 2025-08-10 | Direct | 372,000 |
Reported balance
After 2023-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-10 · Grant · Acquired 372,000 · Balance 372,000 F1: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2023 Filed Aug 11, 2023 22:46 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantStock Options (right to buy) · Derivative | 372,000 | Not disclosed Strike: $12.85 | Not disclosed |
DisclosureSEC source: 0001628280-23-029142 · wk-form4_1691793990.xml · derivative · entry 2 Woo Liyuan · CIK 0001499747 · Former Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,000 Underlying: Common Stock · 372,000 shares Expires 2025-08-10 F1 · kind: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025. F1 · price: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025. F1 · derivative.exercise_date: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 22:46 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | Disposition to issuerStock Options (right to buy) · Derivative | 372,000 | Not disclosed Strike: $12.85 | Not disclosed |
DisclosureSEC source: 0001628280-23-029142 · wk-form4_1691793990.xml · derivative · entry 1 Woo Liyuan · CIK 0001499747 · Former Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 372,000 shares Expires 2031-05-06 F1 · kind: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025. F1 · price: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025. F1 · derivative.exercise_date: The transaction involves an amendment of an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on May 6, 2021 and represented a grant of 744,000 shares of common stock underlying the option under the issuer's 2021 Incentive Award Plan (the "Plan"). As of Aug 10, 2023, the date of the Reporting Person's separation from the issuer (the "Separation Date"), 372,000 shares underlying the option, had vested (the "Vested Options") and the other 372,000 shares underlying the option, had not vested (the "Unvested Options"). Under the Plan, the Unvested Options were forfeited upon separation and the Vested Options would have to be exercised within 90 days of the Separation Date. However, pursuant to the Reporting Person's separation agreement, as filed in Exhibit 10.2 to the issuer's Current Report on Form 8-K filed on Aug 9, 2023, the expiration date of the Vested Options was extended to Aug 10, 2025. Read SEC document |
| April 05, 2023 Filed Apr 6, 2023 22:59 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantClass A Common Stock | 117,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-011056 · wf-form4_168082192757500.xml · nonDerivative · entry 1 Woo Liyuan · CIK 0001499747 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 591,388 F1 · kind: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of April 5, 2023, in each case subject to continued service through the vesting date and certain acceleration rights. F1 · price: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of April 5, 2023, in each case subject to continued service through the vesting date and certain acceleration rights. Read SEC document |
| March 01, 2023 Filed Mar 7, 2023 01:41 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantClass A Common Stock | 18,746 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001818093-23-000009 · wf-form4_167815326366015.xml · nonDerivative · entry 1 Woo Liyuan · CIK 0001499747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,557 F1 · kind: Represents a grant of restricted stock units that vests in one year on the anniversary of the grant date of March 1, 2023, subject to continued service through the vesting date and certain acceleration rights. F1 · price: Represents a grant of restricted stock units that vests in one year on the anniversary of the grant date of March 1, 2023, subject to continued service through the vesting date and certain acceleration rights. F2 · balance_after: These shares include 1,843 shares of Class A Common Stock acquired by the reporting person under the Company's 2021 Employee Stock Purchase Plan Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 01:14 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantClass A Common Stock | 105,633 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001818093-22-000029 · wf-form4_164436923777420.xml · nonDerivative · entry 1 Woo Liyuan · CIK 0001499747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,968 F1 · kind: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. F1 · price: Represents a grant of restricted stock units that vest in one-third increments on each of the first three anniversaries of the grant date of February 4, 2022, in each case subject to continued service through the vesting date and certain acceleration rights. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 23:36 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantPerformance Restricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001818093-21-000065 · wf-form4_163166257469302.xml · derivative · entry 1 Woo Liyuan · CIK 0001499747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F1 · price: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F1 · derivative.exercise_date: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. F1 · derivative.expiration_date: Represents an award of performance-based restricted stock units that may be earned over a four-year performance period based on the achievement of performance goals related to the Company's stock price and continued employment with the Company through the end of the performance period. Each performance restricted stock unit converts on a one-for-one basis to Class A Common Stock upon vesting. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 21:22 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | OtherClass A Common Stock | 728 | $0.00 | $0.00 |
DisclosureSEC source: 0001818093-21-000039 · wf-form4_163001294258006.xml · nonDerivative · entry 1 Woo Liyuan · CIK 0001499747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,335 F1 · kind: The reported acquisition reflects working capital adjustment shares issued pursuant that certain Agreement and Plan of Merger, dated as of December 8, 2020, by and among Vesper Health Acquisition Corp, Hydrate Merger Sub I, Hydrate Merger Sub II LLC, LCP Edge Intermediate, Inc. the indirect parent of Edge Systms LLC d/b/a the HydraFacial Company and LCP Edge Holdco, LLC. F1 · price: The reported acquisition reflects working capital adjustment shares issued pursuant that certain Agreement and Plan of Merger, dated as of December 8, 2020, by and among Vesper Health Acquisition Corp, Hydrate Merger Sub I, Hydrate Merger Sub II LLC, LCP Edge Intermediate, Inc. the indirect parent of Edge Systms LLC d/b/a the HydraFacial Company and LCP Edge Holdco, LLC. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:13 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | OtherClass A Common Stock | 77,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001818093-21-000026 · wf-form4_162673640919243.xml · nonDerivative · entry 1 Woo Liyuan · CIK 0001499747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,607 F1 · kind: The reported acquisition reflects earnout shares issued pursuant that certain Agreement and Plan of Merger, dated as of December 8, 2020, by and among Vesper Health Acquisition Corp, Hydrate Merger Sub I, Hydrate Merger Sub II LLC, LCP Edge Intermediate, Inc. the indirect parent of Edge Systems LLC d/b/a the HydraFacial Company and LCP Edge Holdco, LLC. F1 · price: The reported acquisition reflects earnout shares issued pursuant that certain Agreement and Plan of Merger, dated as of December 8, 2020, by and among Vesper Health Acquisition Corp, Hydrate Merger Sub I, Hydrate Merger Sub II LLC, LCP Edge Intermediate, Inc. the indirect parent of Edge Systems LLC d/b/a the HydraFacial Company and LCP Edge Holdco, LLC. Read SEC document |
| May 20, 2021 Filed May 22, 2021 00:00 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | OtherClass A Common Stock | 269,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001818093-21-000013 · wf-form4_162164159891145.xml · nonDerivative · entry 1 Woo Liyuan · CIK 0001499747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,502 F1 · kind: The reported acquisition is the result of distributions for no consideration made by LCP Edge Holdco LLC to certain of its unitholders, including the reporting person, in redemption of their respective interests in LCP Edge Holdco LLC. Read SEC document |
| May 06, 2021 Filed May 10, 2021 21:26 UTC | SkinHealth Systems Inc. SKIN · Entity 6863 | GrantStock Options (right to buy) · Derivative | 744,000 | $0.00 Strike: $12.85 | $0.00 |
DisclosureSEC source: 0000899243-21-019004 · doc4.xml · derivative · entry 1 Woo Liyuan · CIK 0001499747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,000 Underlying: Common Stock · 744,000 shares Expires 2031-05-06 F1 · security: Represents a grant of stock options under The Beauty Health Company 2021 Incentive Award Plan. Subject to accelerated vesting in certain circumstances, twenty-five percent (25%) of the stock options are scheduled to vest on each of the first four anniversaries of May 6, 2021, as long as the reporting person remains in the service of The Beauty Health Company through the applicable vesting date. F1 · derivative.exercise_date: Represents a grant of stock options under The Beauty Health Company 2021 Incentive Award Plan. Subject to accelerated vesting in certain circumstances, twenty-five percent (25%) of the stock options are scheduled to vest on each of the first four anniversaries of May 6, 2021, as long as the reporting person remains in the service of The Beauty Health Company through the applicable vesting date. Read SEC document |
| August 17, 2016 Filed Oct 24, 2016 08:54 UTC | DIGILITI MONEY GROUP, INC. CAFN · Entity 174754 | GrantStock Option (right to buy) · Derivative | 8,000 | $7.85 Strike: $7.85 | $62,800.00 |
DisclosureSEC source: 0001209191-16-146673 · doc4.xml · derivative · entry 1 Woo Liyuan · CIK 0001499747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2021-08-17 F1 · derivative.exercise_date: This stock option vests in three equal installments on August 17, 2016, 2017 and 2018 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.